Pimple S, Mishra G. Cancer cervix: epidemiology and disease burden. Cytojournal. 2022;19:21.

Article  PubMed  PubMed Central  Google Scholar 

Momenimovahed Z, Mazidimoradi A, Maroofi P, Allahqoli L, Salehiniya H, Alkatout I. Global, regional and national burden, incidence, and mortality of cervical cancer. Cancer Reports. 2023;6(3): e1756.

Article  PubMed  Google Scholar 

Hassanian H, Asadzadeh Z, Baghbanzadeh A, Derakhshani A, Dufour A, Rostami Khosroshahi N, et al. The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. Front Immunol. 2022;13: 938063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doghish AS, Ali MA, Elyan SS, Elrebehy MA, Mohamed HH, Mansour RM, et al. miRNAs role in cervical cancer pathogenesis and targeted therapy: Signaling pathways interplay. Pathol-Res Pract. 2023;244:154386.

Article  CAS  PubMed  Google Scholar 

De Felice F, Marchetti C, Palaia I, Ostuni R, Muzii L, Tombolini V, Panici PB. Immune check-point in cervical cancer. Crit Rev Oncol Hematol. 2018;129:40–3.

Article  PubMed  Google Scholar 

Chandrasekar SV, Singh A, Ranjan A. Overcoming resistance to immune checkpoint inhibitor therapy using calreticulin-inducing nanoparticle. Pharmaceutics. 2023;15(6):1693.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grau J-F, Farinas-Madrid L, Garcia-Duran C, Garcia-Illescas D, Oaknin A. Advances in immunotherapy in cervical cancer. Int J Gynecol Cancer. 2023;33(3):403–13.

Article  PubMed  Google Scholar 

Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. In: Xu J, editor. Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy. Singapore: Springer; 2020. p. 201–26.

Chapter  Google Scholar 

Han X, Chang WW, Xia X. Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer. Front Oncol. 2022;12: 996495.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang YH. Immune checkpoint inhibitors in cancer therapy. J Biomed Res. 2018;32(5):317–26.

Article  CAS  PubMed  Google Scholar 

Lin Q, Wang X, Hu Y. The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells. Cancer Lett. 2023;569: 216318.

Article  CAS  PubMed  Google Scholar 

Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24:65–97.

Article  CAS  PubMed  Google Scholar 

Karpathiou G, Chauleur C, Mobarki M, Peoc’h M. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix. Pathol Res Pract. 2020;216(1): 152782.

Article  CAS  PubMed  Google Scholar 

Pakkala S, Owonikoko TK. Immune checkpoint inhibitors in small cell lung cancer. J Thorac Dis. 2018;10(Suppl 3):S460–7.

Article  PubMed  PubMed Central  Google Scholar 

ElTanbouly M, Zhao Y, Nowak E, Li J, Schaafsma E, Le Mercier I, et al. VISTA is a checkpoint regulator for naıve T cell quiescence and peripheral tolerance. Science. 2020;367:eaay0524.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou Y, Xu Y, Chen X, Zheng L. Advances in the application of immune checkpoint inhibitors in gynecological tumors. Int Immunopharmacol. 2023;117: 109774.

Article  CAS  PubMed  Google Scholar 

Kuang L, He Y. Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy. Int J Clin Exp Pathol. 2020;13(1):26.

PubMed  PubMed Central  Google Scholar 

Kamura T, Ushijima K. Chemotherapy for advanced or recurrent cervical cancer. Taiwan J Obstet Gynecol. 2013;52(2):161–4.

Article  PubMed  Google Scholar 

Karimi G, Ramezani M, Abdi A. Protective effects of lycopene and tomato extract against doxorubicin-induced cardiotoxicity. Phytother Res. 2005;19(10):912–4.

Article  CAS  PubMed  Google Scholar 

Kim DJ, Jang JH, Ham S-Y, Choi SH, Park SS, Jeong SY, et al. Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells. Biochem Biophys Res Commun. 2020;522(2):402–7.

Article  CAS  PubMed  Google Scholar 

Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96(3):805–9.

Article  CAS  PubMed  Google Scholar 

Gupta R, Kadhim MM, Jalil AT, Alasheqi MQ, Alsaikhan F, Mukhamedova NK, et al. The interactions of docetaxel with tumor microenvironment. Int Immunopharmacol. 2023;119: 110214.

Article  CAS  PubMed  Google Scholar 

Majidi M, Safaee S, Amini M, Baghbanzadeh A, Hajiasgharzadeh K, Hashemzadeh S, et al. The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines. Med Oncol. 2021;38:1–8.

Article  Google Scholar 

Marzagalli M, Ebelt ND, Manuel ER, editors. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–50. Elsevier.

Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R. Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers. 2019;11(11):1756.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic mechanisms of resistance to immune checkpoint inhibitors. Biomolecules. 2020;10(7):1061.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pech MF, Fong LE, Villalta JE, Chan LJ, Kharbanda S, O’Brien JJ, et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. Elife. 2019;8: e47362.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Wu L, Zhang J, Wu H, Han E, Guo Q. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. Biochem Biophys Res Commun. 2017;487(1):1–7.

Article  CAS  PubMed  Google Scholar 

Papadimitrakopoulou V, Gadgeel SM, Borghaei H, Gandhi L, Patnaik A, Powell SF, et al. First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. Am Soc Clin Oncol; 2017;35(Suppl 15):9094–9094. https://doi.org/10.1200/JCO.2017.35.15_suppl.9094

Article  Google Scholar 

Meng Y, Liang H, Hu J, Liu S, Hao X, Wong MSK, et al. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer. 2018;9(16):2938.

Article  PubMed  PubMed Central  Google Scholar 

Liang Y, Yu M, Zhou C, Zhu X. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy. Diagn Pathol. 2020;15:1–8.

Article  Google Scholar 

Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE. 2013;8(4): e61895.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018;6(2):189–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol. 2022;40(7):762.

Article  PubMed  Google Scholar 

Wu C, Cao X, Zhang X. VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses. RSC Med Chem. 2021;12(10):1672–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, Xu X-T, Wang L-L, Qin S-B, Zhou J-Y. Expression and clinicopathological significance of Foxp3 and VISTA in cervical cancer. Am J Transl Res. 2021;13(9):10428.

CAS  PubMed  PubMed Central  Google Scholar 

Li N, Yang S, Ren Y, Tai R, Liu H, Wang Y, et al. Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha. Biochem Pharmacol. 2023;210: 115492.

Article  CAS  PubMed  Google Scholar 

Şener GY, Sütcüoğlu O, Öğüt B, Güven DC, Kavuncuoğlu A, Özdemir N, et al. Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo) radiotherapy in head and neck cancer. Strahlenther Onkol. 2023;199(8):761–72.

Article